In This Article:
For Immediate Releases
Chicago, IL – December 9, 2024 – Zacks.com announces the list of stocks and featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include including Berkshire Hathaway Inc. (BRK.B), Exxon Mobil Corp. XOM and Novo Nordisk A/S NVO and Universal Health Realty Income Trust UHT.
Here are highlights from Monday’s Analyst Blog:
Top Research Reports for Berkshire Hathaway, Exxon Mobil and Novo Nordisk
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc., Exxon Mobil Corp. and Novo Nordisk A/S, as well as a micro-cap stock, Universal Health Realty Income Trust. These research reports have been hand-picked from roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Berkshire Hathaway shares have outperformed the Zacks Finance sector (+31.7% vs. +23.4%) as well as the S&P 500 index (+31.7% vs. +27.5%) in the year-to-date period. The Zacks analyst believes that continued insurance business growth fuels float gains and driving earnings. The non-insurance businesses have also been doing well in the last few years. The addition of Pilot Travel Centers has strengthened its energy business. A sturdy capital level provides further impetus.
However, exposure to cat loss induces earnings volatility and also affects underwriting results. Huge capital expenditure remains a headwind. The company is yet to come out of the shadow of Charles Munger’s passing.
(You can read the full research report on Berkshire Hathaway here >>>)
Exxon Mobil shares have outperformed the Zacks Oil and Gas – Integrated - Internationalindustry over the past year (+16.7% vs. +8.8%). The Zacks analyst believes that the acquisition of Pioneer and Guyana ramp-up have enhanced Exxon Mobil’s profitability. Expansion in low-carbon tech, including Baytown's hydrogen facility, positions it for future growth.
Yet, refining margins are pressured due to global capacity increases, with crack spreads softening. Regulatory hurdles in California and XOM’s reliance on finding recoverable reserves add risk.
(You can read the full research report on Exxon Mobil here >>>)
Shares of Novo Nordisk have underperformed the Zacks Large Cap Pharmaceuticalsindustry over the last six months (-23.8% vs. -9.2%). Per the Zacks analyst, the company has faced several setbacks recently. Its insulin icodec in the United States received the FDA’s CRL. A late-stage study on ocedurenone to treat patients with uncontrolled hypertension and CKD had also failed earlier. Moreover, NVO faced allegations from U.S. Senator Bernie Sanders for charging high prices for its semaglutide drugs, Ozempic and Wegovy.